Toronto Dominion Bank Lowers Holdings in BELLUS Health Inc. (NASDAQ:BLU)

Toronto Dominion Bank reduced its stake in shares of BELLUS Health Inc. (NASDAQ:BLU – Get Rating) by 63.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,736 shares of the company’s stock after selling 15,131 shares during the quarter. Toronto Dominion Bank’s holdings in BELLUS Health were worth $72,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its holdings in shares of BELLUS Health by 4,307.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 6,325,067 shares of the company’s stock valued at $43,516,000 after acquiring an additional 6,181,546 shares during the last quarter. Perceptive Advisors LLC lifted its stake in shares of BELLUS Health by 85.2% in the 3rd quarter. Perceptive Advisors LLC now owns 10,247,073 shares of the company’s stock valued at $108,209,000 after purchasing an additional 4,712,904 shares during the last quarter. Pictet Asset Management SA boosted its holdings in shares of BELLUS Health by 111.8% in the 3rd quarter. Pictet Asset Management SA now owns 8,363,294 shares of the company’s stock worth $88,743,000 after purchasing an additional 4,414,746 shares during the period. FMR LLC raised its holdings in BELLUS Health by 1,759.7% during the 2nd quarter. FMR LLC now owns 1,810,083 shares of the company’s stock valued at $16,725,000 after buying an additional 1,712,749 shares during the period. Finally, Polar Capital Holdings Plc lifted its position in BELLUS Health by 62.5% in the first quarter. Polar Capital Holdings Plc now owns 3,250,000 shares of the company’s stock worth $22,360,000 after buying an additional 1,250,000 shares during the last quarter. 90.09% of the stock is currently owned by institutional investors.

BELLUS Health Stock Down 0.1 %

BLU opened at $14.49 on Friday. The stock’s fifty day moving average is $9.90 and its two-hundred day moving average is $9.04. The company has a market capitalization of $1.84 billion, a P/E ratio of -22.29 and a beta of 0.18. BELLUS Health Inc. has a 52 week low of $6.38 and a 52 week high of $14.54.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Jefferies Financial Group cut shares of BELLUS Health from a “buy” rating to a “hold” rating and cut their price objective for the company from $21.00 to $14.75 in a research report on Wednesday, April 19th. Evercore ISI lowered shares of BELLUS Health to an “outperform” rating in a research report on Tuesday, April 18th. Lifesci Capital lowered BELLUS Health from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 18th. Royal Bank of Canada downgraded BELLUS Health from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $21.00 to $14.75 in a report on Tuesday, April 18th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of BELLUS Health in a report on Wednesday, March 22nd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $16.50.

BELLUS Health Company Profile

(Get Rating)

BELLUS Health, Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.